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EUR. RESULTS: The overall prescribing of antiepileptics (N03)
within outpatient setting of Montenegro during investigated
period was 2.85 DTIDs, that was 232516.68 EUR. Although
combination of sodium-valproate and valproic acid was pre-
scribed approximately 13% (0.36 DTIDs), it participated in
total expenses extensively more (40.28%, 93661.92 EUR).
Newer antiepileptic agent, lamotrigin, was prescribed less than
4% (0.11 DTIDs), but It formed a one third of total costs
(€33.28%, €77,377.08). The expenses for the two most fre-
quently prescribed drugs phenobarbital and carbamazepine
were almost equal (€25,439.04 and €21,199.20, 20.06%),
although those drugs formed more than 80% of total prescrib-
ing. The participation of other drugs (sodium-valproate,
clonazepam, gabapentin) in total expenses was about
€14,839.44(6.38%). CONCLUSIONS: Our doctors mostly pre-
scribed older, accessible, long-term experienced and lower
priced antiepileptics. In order to fully estimate the expenses for
the pharmacological management of epilepsy is rational or not,
we have to explore this problem with more detail.
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OBJECTIVES: To evaluate the cost-effectiveness of ruﬁnamide
relative to topiramate and lamotrigine as adjunctive treatment
of Lennox-Gastaut Syndrome (LGS) a severe and devastating
form of childhood epilepsy. METHODS: A Markov state tran-
sition model was developed with 4 health states WC75, WC50,
NC (corresponding to 375%, 350% and <75%, and <50%
reduction in tonic-atonic (drop attack) seizure frequency respec-
tively) and “death”. Efﬁcacy and safety data were obtained
from the literature. Transition probabilities were derived from
patient level trial data for ruﬁnamide. In the absence of head to
head clinical studies, indirect/mixed treatment comparisons
were used to obtain efﬁcacy and safety estimates. LGS related
health state utilities were obtained from a utility study which
was carried out among the UK general public and caregivers/
parents using the time trade off (TTO) method and EQ-5D
questionnaires. Treatment beneﬁt, as reﬂected with percent of
patients achieving a given degree of reduction of drop-attack SF
over a three year horizon, were translated to quality adjusted
life years (QALYs). Medical resource and cost data were
obtained from an expert panel survey and published sources.
Costs were estimated from the perspective of the UK NHS and
personal social services. Probabilistic sensitivity analyses were
carried out. Cost and beneﬁts were discounted according to UK
guidelines. RESULTS: The primary base-case analysis using
TTO utilities found that, over 3 years, ruﬁnamide was associ-
ated with an incremental cost per QALY of £20,538 relative to
topiramate and £154,831 relative to lamotrigine. A secondary
analysis using EQ5D utilities found that ruﬁnamide was asso-
ciated with an incremental cost per QALY of £12,034 relative
to topiramate and £56,446 relative to lamotrigine. CONCLU-
SIONS: This study with its underlying assumptions and data
demonstrates that ruﬁnamide should be considered as a treat-
ment option for LGS, particularly as treatment choice is impor-
tant for this rare and devastating condition.
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OBJECTIVES: To estimate relapse-associated cost savings due to
reduction in MS-related hospitalization rates among natali-
zumab patients with relapsing multiple sclerosis (MS), including
those with highly-active disease. METHODS: A probabilistic
model was developed to estimate natalizumab-associated cost
savings based on reductions in annualized MS-related hospital-
ization rates due to relapse. Hospitalization rate data were
obtained from the randomized, double-blind, placebo-
controlled, phase 3, natalizumab monotherapy clinical trial
(AFFIRM). Among the 942 patients with relapsing MS who
received natalizumab 300 mg (n = 627) or placebo (n = 315)
intravenously for up to 116 weeks, those who reported 2
relapses in the prior year and 1 Gd+ enhancing lesions were
considered highly-active (n = 148 for natalizumab, n = 61 for
placebo). Natalizumab reduced the annualized MS-related hos-
pitalization rate by 65% (p < 0.001) among all patients (0.034
natalizumab vs 0.097 placebo) and by 89% (p < 0.001) among
those with highly-active disease (0.015 natalizumab vs 0.137
placebo). Cost savings associated with such reductions were
assessed using MS hospitalization costs obtained from a random
sample of the PharMetrics database ($19,750/episode, 2007 US
Dollars). The model ran 1,000 simulations to estimate the mean
costs of MS hospitalizations and associated 95% conﬁdence
intervals (CI). RESULTS: Due to relapse-associated hospitaliza-
tion rate reductions, the 2-year per-patient MS hospitalization
cost was $1,338 (95%CI: $842, $1964) for natalizumab and
$3828 (95%CI: $2628, $5281) for placebo, resulting in a cost
savings of $2490 (95%CI: $1,143, $3980). In patients with
highly-active disease, the 2-year per-patient MS hospitalization
cost was $604 (95%CI: $86, $1643) for natalizumab and $5436
(95%CI: $2558, $9593) for placebo, resulting in a cost savings
of $4832 (95%CI: $1988, $9111). CONCLUSIONS: Natali-
zumab signiﬁcantly reduced relapse-associated costs of
MS-related hospitalizations in patients with relapsing MS, with
the magnitude of reduction being even larger among those with
highly-active disease.
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OBJECTIVES: Narcolepsy is a disease resulting in excessive day-
time sleepiness (EDS) and cataplexy (an abrupt temporary loss of
voluntary muscular tone, sometimes evoked by an emotional
stimulus). Narcolepsy affects more than 20,000 people in the UK
and has many implications for health-related quality of life
(HRQL). The objective of our systematic review was to identify
and assess the suitability of instruments used to measure the
impact of narcolepsy on HRQL. METHODS: A systematic
search of Scopus (1966–2008) was conducted using terms syn-
onymous with “narcolepsy” combined with terms associated
with measuring “QoL”. Once the measures were identiﬁed,
further searches were undertaken to explore their use, develop-
ment history and demonstrated measurement properties.
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RESULTS: A total of 141 abstracts were screened yielding 18
studies that used patient-reported outcome (PRO) measures. In
total, 13 PROs were used to evaluate symptoms, sleep disorders,
anxiety/depression, and HRQL, most of which can be more
accurately described as health status (SF-36, EQ-5D) or satisfac-
tion (QLI) measures. Only two PROs were narcolepsy-speciﬁc;
the Ullanlinna Narcolepsy Scale (UNS) and Stanford Narcolepsy
Questionnaire, both measuring symptoms. No narcolepsy-
speciﬁc HRQL questionnaires have been used to date. Generic
measures such as the SF-36, QLI and the EQ-5D can be useful
when making comparisons with other medical conditions but
have limited value for assessing the full impact of narcolepsy
because they include irrelevant items and exclude relevant issues.
Furthermore, the generic measures do not demonstrate measure-
ment properties relevant to this speciﬁc population nor do they
demonstrate adequate development histories as required by regu-
latory bodies. CONCLUSIONS: There is an absence of instru-
ments measuring narcolepsy-speciﬁc HRQL. Existing generic
measures are likely to underestimate the full impact of narcolepsy
on HRQL and therefore underestimate the full potential beneﬁts
of new treatments. A new questionnaire, which adheres to
current regulatory guidelines, is therefore needed to assess the
full impact of narcolepsy on HRQL.
PND21
SYMPTOM SEVERITY IN PARKINSON’S DISEASE SCALE
(SSPDS):A NEW PATIENT-REPORTED OUTCOME MEASURE
OF PARKINSON’S DISEASE SEVERITY
Schröder S, Schaefer M, Martus P
Charité University Medicine, Berlin, Germany
OBJECTIVES: To evaluate the psychometric properties of the
Symptom Severity in Parkinson’s Disease Scale (SSPDS), a new
developed Parkinson’s disease (PD) speciﬁc patient-reported
outcome (PRO) measure reﬂecting the patients’ perspective on
their motor and non-motor symptoms. METHODS: Data were
analyzed from a cross-sectional, community-based sample of
235 patients with idiopathic PD, who completed a set of stan-
dardized questions including the SSPDS, the short-form Parkin-
son’s Disease Questionnaire (PDQ-8) and the EQ-5D.
RESULTS: Conﬁrmatory factor analysis conﬁrmed six factors:
four factors of health status (“bodily discomfort”, “mobility”,
“cognitive functioning” and “emotional well-being”), one
factor for the total health status, and one of non-motor symp-
toms worsened by ADRs (ADR_NMS score). The 23-item
SSPDS showed excellent internal consistency (Cronbach’s alpha
between 0.70 and 0.89 for all health state scores, mean alpha
was 0.79). Reproducibility for the total score (ICC = 0.82) was
high. ICC for single scores ranged from 0.42 for bodily dis-
comfort to 0.88 for mobility. Concurrent validity for the total
and individual SSPDS scores was good as reﬂected by high
Pearson’s r correlations with the PDQ-8 (r = 0.59 for cognitive
functioning to r = 0.77 for the total score) and moderate to
high correlations with the EQ-5D (r = -0.40 to r = -0.64). The
ADR_NMS score was clearly separated from the other SSPDS
scores, as shown by low correlations with the SSPDS health
status scores (r = 0.19 for emotional well-being to r = 0.33 for
mobility) and other measures (r = -0.14 for the EQ-5D VAS to
r = -0.24 for the PDQ-8). CONCLUSIONS: The SSPDS is a
valid and reliable PD-speciﬁc PRO measure to evaluate the
severity of motor and non-motor symptoms. These symptoms
load on the health status dimensions “bodily discomfort”,
“mobility”, “cognitive functioning” and “emotional well-
being”. Additionally, it identiﬁes symptoms that are caused or
affected by adverse drug reactions (ADRs). It is short and easy
to complete in daily routine.
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OBJECTIVES: To capture utility values for health states related
to Lennox-Gastaut Syndrome (LGS), a severe form of childhood
epileptic encephalopathy. METHODS: Four health state (HS)
descriptions of LGS outcomes and 5 HS descriptions of common
adverse events of anti-epileptic treatments for LGS were devel-
oped following literature review and extensive consultation with
clinical experts. HSs were deﬁned by tonic-atonic (drop attack)
seizure frequency (SF). For LGS outcomes, the anchor state
(HS-1) was described by frequency of 21–28 seizures per week;
HS-2 a reduction of <50% in SF; HS-3 a reduction of 350% and
<75% in SF and HS-4 a 375% reduction in SF. All HSs were
piloted with 9 members of the UK general public. Time trade off
interviews (TTO) were conducted with 119 members of the
general public of whom 48% were caregivers/parents of children
aged 4 to 18. A secondary analysis involved the participants
rating each LGS health state on a visual analogue scale (VAS) and
using the EQ5D. RESULTS: The mean utility scores for HS-1,
HS-2, H-S3 and HS-4 were 0.393, 0.461, 0.605 and 0.699
respectively using TTO; 0.02, 0.414, 0.556 and 0.677 respec-
tively using VAS; 0.02, 0.100, 0.500 and 0.596 respectively using
EQ-5D. Differences between all LGS HSs and the anchor HS
were signiﬁcant (p < 0.0001) except for HS-2 using EQ5D. The
preferences were reasonably consistent across age groups and
gender. Caregivers/parents gave slightly higher scores for the
health states only via TTO method. For adverse events the dis-
utility score was 0.108 for concentration problems, 0.135 for
weight loss, 0.174 for somnolence, 0.190 for rash and 0.193 for
Nausea/Vomiting. CONCLUSIONS: The results demonstrate
that drop attack SF correlates with poorer quality of life and
show in a UK community sample a preference for treatment
outcomes associated with a greater than 50% reduction in drop
attack SF.
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Introduction:Generic health-related quality of life data such as
those obtained from the EQ-5D are not always available in a
clinical programme. However, these data are required in reim-
bursement submissions. In the absence of direct measurement,
such data may be estimated by mapping from a disease speciﬁc
instrument. OBJECTIVES: 1) To map the elements in disease
speciﬁc IRLS (International Restless Leg Scale) questionnaire
against the elements in EQ-5D, and 2) To determine the relation-
ship between changes in the EQ-5D derived utility scores and
changes in the IRLS sum scores. METHODS: Each level of each
question in the IRLS questionnaire, was mapped against a level
of the EQ-5D based on clinical experts’ opinion. The utility
scores were subsequently derived for two phase III clinical studies
using the established algorithm. Simple OLS regression analyses
were performed for the changes in utility scores on the changes in
the IRLS sum scores from baseline to end of the maintenance
period in order to estimate the average impact of a unit change
on the IRLS for utility. RESULTS: Mobility and self-care dimen-
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